Vanguard Group Inc Lipocine Inc. Transaction History

Vanguard Group Inc

  • $5.46 Trillion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 10, 2023
BUY
$0.37 - $8.65 $745 - $17,438
2,016 Added 0.05%
3,799,298 $1.52 Million
Q1 2022

May 13, 2022
SELL
$0.89 - $1.85 $11,292 - $23,472
-12,688 Reduced 0.33%
3,797,282 $5.2 Million
Q4 2021

Feb 14, 2022
SELL
$0.99 - $1.2 $5,324 - $6,453
-5,378 Reduced 0.14%
3,809,970 $3.78 Million
Q2 2021

Aug 13, 2021
BUY
$1.17 - $1.59 $4.46 Million - $6.07 Million
3,815,348 New
3,815,348 $5.34 Million

About Lipocine Inc.

LPCN Quotes by TradingView
  • Ticker LPCN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 88,510,800
  • Market Cap $431M
  • Description
  • Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone rep...
More about LPCN
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email